Product Images Clopidogrel

The text describes a figure (Figure 1) showing the exposure to Clopidogrel Active Metabolite with multiple doses of Clopidogrel Bisulfate 75mg alone or with Proton Pump Inhibitors (PPIs). The figure shows the effect of co-administered PPI on the active metabolite AUC and the mean and 90% confidence interval. The PPIs included Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole. The figure also shows the change relative to Clopidogrel Bisulfate administered alone.*

This is a chart showing the cumulative event rate for cardiovascular death, myocardial infarction, and stroke over the course of 12 months of follow-up. The chart includes data for both a placebo group (given aspirin alone) and a group given clopidogrel bisulfate along with aspirin. Other standard therapies were also used as appropriate. The chart shows a statistically significant difference in outcomes between the two groups, with the clopidogrel bisulfate group having a lower cumulative event rate.*

This appears to be a table with various medical data including demographics such as gender and race, history of medical conditions such as diabetes and stroke, and treatment plans like the use of HeparinLMWH and Aspirin. The table also seems to include results from a study with a placebo and Clopidogrel Bisulate, as well as a hazard ratio calculation.*

The text describes a clinical trial in which the efficacy of Clopidogrel compared to a Placebo was evaluated, using the percentage of deaths before the first discharge as the endpoint. The results show a 7% proportional risk reduction with Clopidogrel, evidenced by a lower mortality rate (1726 deaths, 7.5%) compared to Placebo (1845 deaths, 8.1%). The risk reduction is statistically significant (p=0.03). The graph displays the number of deaths over time since randomization (up to 28 days) for both groups.*

The text appears to be a table displaying the results of a clinical trial evaluating the effectiveness of a drug called Clopidogrel. The table compares the incidence of adverse events, including death, re-infarction, and stroke, between patients who received Clopidogrel and those who received a placebo. The results indicate a 9% proportional risk reduction in adverse events with Clopidogrel compared to the placebo. The x-axis represents the number of days since randomization, up to 28 days.*

This appears to be a graph depicting the cumulative event rate of fatal or non-fatal vascular events in relation to aspirin and clopidogrel bisulfate over the course of 36 months of follow-up.*

This appears to be a table or chart showing the number of patients with certain conditions (Stroke, Mi, PAD, Overall) and the percentage of patients prescribed certain medications (Clopidogrel Bisulfate, Aspirin). The table also includes a section titled "Favors" and two columns of dates. The meaning of the dates and "Favors" section is not clear without additional context. The chart seems to be measuring the hazard ratio but the value is not included in the text.*